Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 8/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL474906 | 0.89 | KCNH2 (0.53) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL30065291 | 0.89 | KCNH2 (0.53) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL4776313 | 0.89 | KCNH2 (0.53) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL877954 | 0.87 | KCNH2 (0.56) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL895603 | 0.86 | KCNH2 (0.47) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL5307774 | 0.85 | NR1I2 (0.60) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL14009599 | 0.85 | NR1I2 (0.57) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL3893256 | 0.85 | NR1I2 (0.61) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL14009596 | 0.84 | NR1I2 (0.58) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL3893542 | 0.84 | NR1I2 (0.61) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2022-11-10 | — | — | US | disclosed |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2020-08-20 | — | — | US | disclosed |
| EP-2953461-B1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME (US) | 2020-04-22 | — | — | EP | disclosed |
| EP-2953462-B1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-2780026-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-2953456-B1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME (US) | 2019-05-22 | — | — | EP | disclosed |
| US-20190127365-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2019-05-02 | — | — | US | disclosed |
| EP-2086982-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9738661-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MERCK SHARP & DOHME CORP. | 2009-05-07 | — | — | US | disclosed |
| US-20090075869-A1 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME LLC | 2009-03-19 | — | — | US | disclosed |
| US-7470664-B2 | HCV NS3 protease inhibitors | MERCK & CO., INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080255038-A1 | 3-[(R)-2-(N,N-dimethylamino)ethylthio-Sar]-4-(gamma-hydroxymethylleucine)cyclosporin, for example, and pharmaceutical compositions prepared from the same, in combination with one or more NS5B polymerase inhibitors; use in treatment of hepatitis C virus; avoids need to use interferon or ribavirin | SCYNEXIS, INC. | 2008-10-16 | — | — | US | disclosed |
| WO-2008079206-A1 | NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | MERCK & CO., INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008057208-A2 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| EP-1915053-A2 | NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES | Merck & Co., Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007022073-A2 | NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070027071-A1 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME LLC | 2007-02-01 | — | — | US | disclosed |
| US-20060100262-A1 | Tetracyclic indole derivatives as antiviral agents | ISTITUTO DI RICHERCHEDI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IRMB) (IT) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027071-A1 | HCV NS3 protease inhibitors | HAVCR2, GTF3C3, CTSC | NR1I2 613/4885KCNH2 4405/4885CYP3A4 154/4885 |
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | NR1I2 643/4885KCNH2 4621/4885CYP3A4 1646/4885 |
| US-20080255038-A1 | 3-[(R)-2-(N,N-dimethylamino)ethylthio-Sar]-4-(gamma-hydroxymethylleucine)cyclosporin, for example, and pharmaceutical compositions prepared from the same, in combination with one or more NS5B polymerase inhibitors; use in treatment of hepatitis C virus; avoids need to use interferon or ribavirin | NSUN2, TPMT, EIF5B | NR1I2 242/4885KCNH2 4505/4885CYP3A4 227/4885 |
| US-20090075869-A1 | HCV NS3 protease inhibitors | HAVCR2, GTF3C3, CTSC | NR1I2 613/4885KCNH2 4405/4885CYP3A4 154/4885 |
| US-20060100262-A1 | Tetracyclic indole derivatives as antiviral agents | IDO1, ZC3HAV1, IDO2 | NR1I2 144/4885KCNH2 1341/4885CYP3A4 189/4885 |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | HAVCR2, HCCS, EIF2AK2 | NR1I2 643/4885KCNH2 4621/4885CYP3A4 1646/4885 |
| US-20190127365-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | NR1I2 643/4885KCNH2 4621/4885CYP3A4 1646/4885 |
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | NR1I2 643/4885KCNH2 4621/4885CYP3A4 1646/4885 |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MTAP, NT5C3B, NSUN2 | NR1I2 1191/4885KCNH2 3281/4885CYP3A4 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.